Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Must have received: corticosteroid

disease recurrence or progression despite treatment with corticosteroids

Must have received: immunosuppressant (azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, methotrexate)

disease recurrence or progression despite treatment with ... immunosuppressants (e.g., azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, methotrexate)

Must have received: biologic (rituximab)

disease recurrence or progression despite treatment with ... biologics (e.g., rituximab)

Cannot have received: CAR-T cell therapy

Any history of CAR-T ... therapy targeting any antigen

Cannot have received: TCE therapy

Any history of ... TCE therapy targeting any antigen

Cannot have received: BCMA-targeted therapy

Any history of ... BCMA-targeted therapy

Cannot have received: immunosuppressive drug (not listed)

Exception: unless approved by the medical monitor

Use of any approved immunosuppressive drugs not listed here within 12 weeks or 5 half-lives (whichever is longer) before screening, unless approved by the medical monitor

Cannot have received: investigational non-biological agent

Participation in any investigational trial involving non-biological agents within 4 weeks or 5 half-lives (whichever is longer) ... before screening

Cannot have received: investigational biological agent

Participation in any investigational trial involving biological agents within 12 weeks or 5 half-lives (whichever is longer) ... before screening

Cannot have received: live vaccine

Administration of live vaccines within 4 weeks before screening